Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FX-111 |
| Synonyms | |
| Therapy Description |
FX-111 is a heterobifunctional androgen receptor (AR) degrader, which potentially inhibits androgen-dependent transcription and decreases tumor growth (Cancer Res (2026) 86 (7_Supplement): 5784). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FX-111 | FX111|FX 111 | Hormone - Anti-androgens 59 | FX-111 is a heterobifunctional androgen receptor (AR) degrader, which potentially inhibits androgen-dependent transcription and decreases tumor growth (Cancer Res (2026) 86 (7_Supplement): 5784). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07719361 | Phase I | FX-111 | A Study in Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |